par Rozenberg, Serge 
;Joris, A.;Albert, V.;Antoine, Caroline ;Vandromme, Jean
Référence Revue médicale de Bruxelles, 39, 4, page (259-263)
Publication Publié, 2018-09
;Joris, A.;Albert, V.;Antoine, Caroline ;Vandromme, Jean Référence Revue médicale de Bruxelles, 39, 4, page (259-263)
Publication Publié, 2018-09
Article révisé par les pairs
| Résumé : | Postmenopausal hormone therapy (MHT) is mainly used for the relief of menopausal symptoms. It can also be prescribed for the treatment of postmenopausal osteoporosis, but nowadays, other medications are given to older patients for this indication. Current, available data, demonstrates that MHT is beneficial as well as safe for postmenopausal, symptomatic women. Modern regimens of MHT comprise lower dosages of estrogens than in the past, either safer progestins or SERMs. These regimens should be the preferred option for women with a uterus. Non-androgenic progestin may present reduced thrombotic and breast cancer risks, and transdermal oestrogen could have a reduced thrombotic risk. Oestrogen-only therapy is the preferred option for women who underwent a hysterectomy. Vaginal oestrogen therapy is indicated for women with atrophic vaginitis and recurrent urinary tract infections. |
